In concordance with the aforementioned changes observed in the patient tumours, the post-dacomitinib MGG70RR-GSC xenografts exhibited reduced levels of EGFR/phospho-EGFR expression as well as reduced MIB-1 labeling index, i.e., the proliferation rate (P = 0.007), compared to the pre-dacomitinib MGG70R-GSC xenografts (Figs 4C,D). The gene discussed is EGFR; the disease is neoplasm.